Biggest losers shed 22 pounds in Qnexa weight loss drug trial - PulmCCM
Advertisement
Apr 252011
 

Fen-phen died in court, but phenteramine was cleared of all serious charges. Gadde et al report phase III results for Qnexa (by Vivus), a phenteramine-topiramate combination. Over 56 weeks, takers of a double-dose of study drug lost 10 kg; single-dose, 8 kg; and placebo, 1.4 kg. There were plenty of side effects (dry mouth and paresthesias 20%; dysgeusia, insomnia, dizziness, depression & anxiety-related adverse events each in 7% or more at the high dose).(n=2,487). Lancet 2011;377:1341-1352.

Liked this post? Get a weekly email update (no spam, ever), and explore our library of clinical guidelines, practice updatesreview articles. and board review questions.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society or journal referenced on the website.

Leave a Comment